Cdt Equity Inc. (CDTTW) — 8-K Filings

8-K Filings (29)

• CDT Equity Inc. Files 8-K on Material Agreement & Equity Sales — Dec 12, 2025 Risk: medium
  CDT Equity Inc. filed an 8-K on December 12, 2025, reporting on events that occurred on December 8, 2025. The filing indicates an entry into a material definiti
• CDT Equity Inc. Files 8-K on Security Holder Rights — Oct 9, 2025 Risk: medium
  CDT Equity Inc. filed an 8-K on October 9, 2025, reporting events as of October 8, 2025. The filing indicates material modifications to the rights of security h
• CDT Equity Inc. Files 8-K: Director Changes, Bylaw Amendments — Aug 8, 2025 Risk: medium
  CDT Equity Inc. filed an 8-K on August 8, 2025, reporting on several key events including the departure of directors, election of new directors, appointment of
• Conduit Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Jun 9, 2025 Risk: medium
  Conduit Pharmaceuticals Inc. announced on June 3, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of e
• Conduit Pharmaceuticals Files 8-K on Shareholder Nominations — Jun 3, 2025 Risk: medium
  Conduit Pharmaceuticals Inc. filed an 8-K on June 3, 2025, to report shareholder nominations pursuant to Exchange Act Rule 14a-11. The company, formerly known a
• Conduit Pharmaceuticals Files 8-K on Security Holder Rights — May 16, 2025 Risk: medium
  Conduit Pharmaceuticals Inc. filed an 8-K on May 16, 2025, reporting material modifications to security holder rights and amendments to its articles of incorpor
• Conduit Pharmaceuticals Files 8-K on Shareholder Votes — May 6, 2025 Risk: low
  Conduit Pharmaceuticals Inc. filed an 8-K on May 5, 2025, reporting on matters submitted to a vote of its security holders. The company, formerly known as Murph
• Conduit Pharmaceuticals Files 8-K: Accountant Change & Financials — Apr 25, 2025 Risk: medium
  Conduit Pharmaceuticals Inc. filed an 8-K on April 25, 2025, reporting changes in its certifying accountant and filing financial statements and exhibits. The co
• Conduit Pharmaceuticals Announces Board and Compensation Changes — Apr 16, 2025 Risk: medium
  Conduit Pharmaceuticals Inc. announced on April 12, 2025, a change in its board of directors and executive compensation arrangements. The company, formerly know
• Conduit Pharmaceuticals Reports Material Agreement and Equity Sales — Apr 4, 2025 Risk: medium
  Conduit Pharmaceuticals Inc. filed an 8-K on April 4, 2025, reporting on two key events that occurred on March 31, 2025: entering into a material definitive agr
• Conduit Pharmaceuticals Files 8-K — Apr 1, 2025 Risk: medium
  Conduit Pharmaceuticals Inc. filed an 8-K on April 1, 2025, reporting an event that occurred on March 31, 2025. The filing indicates a change in the company's s
• Conduit Pharmaceuticals Files Current Report — Mar 6, 2025 Risk: low
  Conduit Pharmaceuticals Inc. filed an 8-K on March 6, 2025, reporting an event on March 5, 2025. The company, formerly known as Murphy Canyon Acquisition Corp.
• Conduit Pharmaceuticals Faces Delisting, Terminates Agreement — Feb 19, 2025 Risk: high
  Conduit Pharmaceuticals Inc. announced on February 12, 2025, the termination of a material definitive agreement. The company also provided notice of delisting o
• Conduit Pharmaceuticals to Acquire 03 Life Sciences — Feb 11, 2025 Risk: medium
  Conduit Pharmaceuticals Inc. announced on February 7, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of common stock of
• Conduit Pharmaceuticals Files 8-K on Security Holder Rights — Jan 23, 2025 Risk: medium
  Conduit Pharmaceuticals Inc. filed an 8-K on January 23, 2025, reporting material modifications to the rights of security holders and amendments to its articles
• Conduit Pharmaceuticals Inc. Files 8-K on Shareholder Vote — Jan 14, 2025 Risk: low
  Conduit Pharmaceuticals Inc. filed an 8-K on January 14, 2025, reporting on matters submitted to a vote of security holders on January 13, 2025. The company, fo
• Conduit Pharmaceuticals Faces Nasdaq Delisting — Dec 20, 2024 Risk: high
  Conduit Pharmaceuticals Inc. reported on December 17, 2024, that it received a notice of delisting from the Nasdaq Stock Market due to failure to meet continued
• Conduit Pharmaceuticals Enters Material Agreement, Discloses Equity Sales — Dec 17, 2024 Risk: medium
  Conduit Pharmaceuticals Inc. announced on December 12, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales
• Conduit Pharmaceuticals Files 8-K: Agreements, Obligations, and Equity Sales — Nov 25, 2024 Risk: medium
  Conduit Pharmaceuticals Inc. entered into a material definitive agreement on November 22, 2024. The company also incurred a direct financial obligation or an ob
• Conduit Pharmaceuticals Files 8-K on Corporate Changes — Nov 19, 2024 Risk: medium
  Conduit Pharmaceuticals Inc. filed an 8-K on November 19, 2024, reporting on events as of November 14, 2024. The filing covers the departure of directors, elect
• Conduit Pharmaceuticals Restates Financials — Nov 14, 2024 Risk: high
  Conduit Pharmaceuticals Inc. announced on November 12, 2024, that it will not rely on previously issued financial statements or related audit reports. This foll
• Conduit Pharmaceuticals Reports Material Agreements & Equity Sales — Nov 1, 2024 Risk: medium
  On October 28, 2024, Conduit Pharmaceuticals Inc. entered into a material definitive agreement and also terminated a material definitive agreement. The company
• Conduit Pharmaceuticals Enters Material Definitive Agreement — Oct 15, 2024 Risk: medium
  On October 9, 2024, Conduit Pharmaceuticals Inc. entered into a material definitive agreement. This agreement also creates a direct financial obligation or an o
• Conduit Pharmaceuticals Files 8-K on Shareholder Nominations — Sep 6, 2024 Risk: medium
  Conduit Pharmaceuticals Inc. filed an 8-K on September 6, 2024, to report shareholder nominations pursuant to Exchange Act Rule 14a-11. The company, formerly kn
• Conduit Pharmaceuticals Faces Nasdaq Listing Rule Non-Compliance — Aug 16, 2024 Risk: high
  Conduit Pharmaceuticals Inc. announced on August 15, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules.
• Conduit Pharmaceuticals Inc. Files 8-K — Aug 8, 2024 Risk: medium
  On August 7, 2024, Conduit Pharmaceuticals Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securiti
• Conduit Pharmaceuticals Inc. Files 8-K: Material Agreements & Equity Sales — Aug 7, 2024 Risk: medium
  On August 6, 2024, Conduit Pharmaceuticals Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported
• Conduit Pharmaceuticals Files 8-K on Shareholder Nominations — Jul 1, 2024 Risk: medium
  Conduit Pharmaceuticals Inc. filed an 8-K on July 1, 2024, to report shareholder nominations pursuant to Exchange Act Rule 14a-11. The company, formerly known a
• Conduit Pharmaceuticals Fails Listing Rule — May 31, 2024 Risk: high
  Conduit Pharmaceuticals Inc. received a notice on May 28, 2024, indicating it failed to meet a continued listing rule or standard for its securities. The compan

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX